Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Avanos Medical, Inc. (NYSE: AVNS), a medical technology company headquartered in Alpharetta, Georgia. Through these filings, investors can review how Avanos reports its financial performance, strategic actions and governance matters related to its Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R) segments.
Avanos uses current reports on Form 8-K to disclose material events. These include earnings releases that present quarterly and year-to-date results, segment net sales and operating income, and non-GAAP measures such as adjusted operating income, adjusted net income, adjusted diluted earnings per share, adjusted EBITDA and free cash flow. The company explains in these filings which items are excluded from non-GAAP measures, such as acquisition and integration charges, restructuring and transformation expenses, EU Medical Device Regulation compliance costs, amortization of acquisition-related intangibles, impairments, certain tax effects and currency impacts.
Form 8-K filings also document strategic portfolio moves and organizational changes. Avanos has furnished press releases describing the divestiture of its Hyaluronic Acid product line to Channel-Markers Medical, the agreement for WRS Group to acquire its US Game Ready orthopedic rental business and the acquisition of Nexus Medical, LLC. Other 8-K items cover executive appointments, board changes and an organizational restructuring that eliminated certain senior roles, along with details of severance and equity treatment under the company’s established plans.
Stock Titan enhances these regulatory disclosures with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the implications of earnings releases, transaction announcements and governance updates. Real-time ingestion of EDGAR data means new Avanos Forms 8-K and other SEC documents appear promptly, while AI-generated overviews and tagging make it easier to locate information on segment performance, non-GAAP reconciliations and executive compensation arrangements.
Avanos Medical, Inc. received an updated ownership report showing that Robert G. Moses Capital, LLC now reports beneficial ownership of 0 shares of Avanos common stock, representing 0.0% of the outstanding class as of 12/31/2025.
The filer confirms it owns 5 percent or less of the stock class and has no sole or shared power to vote or dispose of any shares. It also certifies that any securities referenced were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Avanos Medical.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting its beneficial ownership of Avanos Medical Inc common stock. Dimensional reports beneficial ownership of 2,157,531 shares of Avanos Medical, representing 4.6% of the outstanding common stock as of the event date 12/31/2025. It reports sole power to vote 2,087,813 shares and sole power to dispose of 2,157,531 shares, with no shared voting or dispositive power.
The shares are owned by various funds and accounts advised or managed by Dimensional or its subsidiaries, and Dimensional states that it may be deemed a beneficial owner because it has voting and/or investment power. Dimensional disclaims beneficial ownership of these securities and indicates that each underlying fund’s interest is below 5% of the class. The filing also certifies that the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Avanos Medical.
Avanos Medical, Inc. filed a current report describing an investor presentation being given at the JP Morgan Healthcare Conference. On January 13, 2026, the company will present and discuss a slide deck that is included as Exhibit 99.1 to this report and incorporated by reference for informational purposes.
The company clarifies that the materials furnished under Regulation FD are not considered “filed” under the Securities Exchange Act and are not subject to related liability provisions. These materials will also not be automatically incorporated into any securities registration statements or other documents unless specifically stated in those future filings.
Avanos Medical filed an amended report to clarify severance terms for two departing executives as part of a broader organizational restructuring. The company eliminated the roles of Chief Commercial Officer and General Counsel, notifying Kerr Holbrook and Mojirade James that their employment would end effective December 1, 2025, with their responsibilities reassigned to other employees.
Under the Severance Pay Plan, Avanos will pay Mr. Holbrook $1,535,417 and Ms. James $1,425,665 in cash severance and cover 100% of their COBRA premiums for 12 months. Time-based restricted stock units for both executives vested pro rata on December 1, 2025, while performance-based awards will vest based on actual performance. The amendment specifies that all 16,300 time-based restricted stock units granted to Ms. James on April 22, 2025 vested in full on that date, and their stock options remain exercisable for up to five years, subject to standard conditions and release agreements.
Avanos Medical, Inc. executive Kerr W. Holbrook, the SVP and Chief Commercial Officer, reported open-market sales of company common stock. On 11/18/2025, he sold a total of 15,000 shares of Avanos Medical common stock in several transactions at prices ranging from $11.00 to $11.02 per share. After these sales, Holbrook directly beneficially owned 83,860 shares of Avanos Medical common stock.
AVNS
Armistice Capital, LLC and Steven Boyd filed a Schedule 13G reporting beneficial ownership of 2,500,000 shares of Avanos Medical, Inc. (AVNS) common stock, representing 5.39% of the class. They report shared voting and shared dispositive power over these shares, with no sole voting or dispositive power. The filing cites 46,418,907 shares outstanding as of October 29, 2025 (per the issuer’s 10‑Q).
The filing is certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control. The date of the event requiring the filing is September 30, 2025.
Avanos Medical (AVNS) reported Q3 2025 results showing modest top-line growth but weaker profitability. Net sales were $177.8 million versus $170.4 million a year ago, driven by Specialty Nutrition Systems (SNS) at $114.0 million and Pain Management & Recovery (PM&R) at $59.0 million. Gross profit fell to $86.0 million from $92.9 million as cost of products sold increased. Operating income was $0.1 million, and the company posted a net loss of $1.4 million (diluted EPS $(0.03)).
Year to date, net sales reached $520.3 million versus $508.2 million, with an operating loss of $64.1 million reflecting a $77.0 million goodwill impairment in PM&R recorded earlier in 2025. Net loss was $71.6 million (diluted EPS $(1.55)). Cash and cash equivalents were $70.5 million, down from $107.7 million at year-end, after funding investments and debt repayments; the revolver was reduced to $0 and the term loan stood at $103.1 million.
Strategic moves included acquiring Nexus Medical for $27.0 million in cash (up to $20.0 million contingent). The deal added $0.9 million of net sales since closing and brought $20.5 million of identifiable intangibles and $14.0 million of goodwill. Restructuring continued, with $10.3 million in Q3 costs; management expects up to $10.0 million additional expenses and annualized savings of $15.0–$20.0 million as initiatives extend through 2026.
Avanos Medical, Inc. filed an 8-K to announce results for the three and nine months ended September 30, 2025. The company reported its results of operations and financial condition for these periods.
The announcement was provided via a press release furnished as Exhibit 99.1. The company stated the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act.
The Vanguard Group filed Amendment No. 12 to Schedule 13G on Avanos Medical (AVNS), reporting beneficial ownership of 3,425,214 shares of common stock, representing 7.38% of the class as of 09/30/2025. Vanguard reports 0 shares with sole voting power and 371,596 with shared voting power. It has 2,979,548 shares with sole dispositive power and 445,666 with shared dispositive power.
Vanguard is identified as an investment adviser and certifies the holdings were acquired and are held in the ordinary course of business and not to change or influence control. Dividends and sale proceeds are for Vanguard’s clients, including registered investment companies and other managed accounts, with no single client over 5%.
FAQ
What is the current stock price of Avanos Medical (AVNS)?
What is the market cap of Avanos Medical (AVNS)?
